These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 25701264)

  • 1. How should I treat subacute stent thrombosis in the context of brain haemorrhage with abciximab?
    Martin-Yuste V; Alvarez-Contreras L; Sabaté M; Kelbaek H; Saunamäki K; Jørgensen E; Kocka V
    EuroIntervention; 2015 Feb; 10(10):e1-6. PubMed ID: 25701264
    [No Abstract]   [Full Text] [Related]  

  • 2. Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention--caution regarding the combined use of aspirin, ticlopidine and abciximab.
    Alvarez JM; Harper RW; Peverill RE
    Aust N Z J Med; 1998 Aug; 28(4):463-4. PubMed ID: 9777116
    [No Abstract]   [Full Text] [Related]  

  • 3. Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction.
    Berglund U; Nilsson L; Janzon M
    Scand Cardiovasc J; 2013 Aug; 47(4):230-5. PubMed ID: 23692139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature.
    Makoni SN
    Heart; 2001 Dec; 86(6):E18. PubMed ID: 11711483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abciximab-induced thrombocytopenia: management of bleeding in the setting of recent coronary stents.
    Nowakowski K; Rogers J; Nelson G; Gunalingam B
    J Interv Cardiol; 2008 Feb; 21(1):100-5. PubMed ID: 18194210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ["Triple therapy" with warfarin, clopidogrel and acetylsalicylic acid. High risk treatment with unclear benefit].
    Wallén H; Agren A; Nekludov M
    Lakartidningen; 2007 Nov 28-Dec 4; 104(48):3640-2. PubMed ID: 18193674
    [No Abstract]   [Full Text] [Related]  

  • 11. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
    Pinkau T; Ndrepepa G; Kastrati A; Mann JF; Schulz S; Mehilli J; Schömig A
    Cardiology; 2008; 111(4):247-53. PubMed ID: 18434733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
    Rangé G; Yayehd K; Belle L; Thuaire C; Richard P; Cazaux P; Barbou F; Köning R; Chassaing S; Teiger E; Berthier R; Decomis MP; Claudel JP; Delarche N; Brunel P; De Poli F; Dupouy P; Beygui F; Albert F; Collet JP; Montalescot G;
    Arch Cardiovasc Dis; 2014 Apr; 107(4):225-35. PubMed ID: 24794216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abciximab-induced thrombocytopenia.
    Griffiths C; Fisher M
    QJM; 2002 Sep; 95(9):635-6. PubMed ID: 12205341
    [No Abstract]   [Full Text] [Related]  

  • 15. Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction.
    Xia JG; Qu Y; Shen H; Liu XH
    Coron Artery Dis; 2013 Sep; 24(6):522-6. PubMed ID: 23900046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary hemorrhage and acute pulmonary thromboembolism after abciximab administration.
    Conrotto F; Scacciatella P; Usmiani T; Grasso C; Ebrille E; D'Amico M; Marra S
    Am J Emerg Med; 2013 Feb; 31(2):450.e1-2. PubMed ID: 22980359
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab.
    Alvarez JM
    J Thorac Cardiovasc Surg; 1998 Feb; 115(2):472-3. PubMed ID: 9475547
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.